Amphastar Pharmaceuticals
AMPH
223 hedge funds and large institutions have $1.06B invested in Amphastar Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 90 increasing their positions, 74 reducing their positions, and 14 closing their positions.
171% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 14
22% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 74
10% more funds holding
Funds holding: 203 → 223 (+20)
0.63% more ownership
Funds ownership: 61.95% → 62.58% (+0.63%)
1% less capital invested
Capital invested by funds: $1.07B → $1.06B (-$8.11M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
90% less call options, than puts
Call options by funds: $6.06M | Put options by funds: $60.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$9.81M |
| 2 |
Morgan Stanley
New York
|
+$9.43M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.81M |
| 4 |
Goldman Sachs
New York
|
+$7.61M |
| 5 |
CM
Castleark Management
Chicago,
Illinois
|
+$6.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$12.7M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7.99M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$7.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7.01M |
| 5 |
PCM
Penserra Capital Management
Orinda,
California
|
-$6.42M |
AMPH Hedge Fund Activity: Q2 2022 in Review
223 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2022, worth a combined $1.06B — down 0.76% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AMPH positions and 14 closed out — a net gain of 24 holders — while 90 added to existing stakes and 74 trimmed.
The largest buyer was Portolan Capital Management, opening a new position worth an estimated $9.81M. The largest seller was Janus Henderson Group, cutting an estimated $12.7M.
- 223 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2022, up from 203 in Q1 2022.
- Funds reported $1.06B of Amphastar Pharmaceuticals stock for Q2 2022, down 0.76% quarter-over-quarter.
- 38 funds opened new Amphastar Pharmaceuticals positions in Q2 2022 and 14 closed out, a net change of +24 holders.
- The largest Amphastar Pharmaceuticals buyer in Q2 2022 was Portolan Capital Management, an estimated $9.81M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2022 was Janus Henderson Group, an estimated $12.7M sold.
Based on aggregated 13F filings for Q2 2022.